Diamyd Medical AB (publ) (DMYD-B)
Stockholm Exchange · Sweden · prices in SEK · close of 20 Oct 2026
Key indicators
| Last close | SEK 1.010 |
|---|---|
| 52-week range | 0.896 – 17.880 |
| Return, 1 month / 3 months | −1.6% / −1.9% |
| Return, 1 year / 3 years | −90.8% / −87.1% |
| Trend | Below its 200-day average |
| RSI (14) | 49 |
| Volatility (1 year) | 231.7% |
| Worst drawdown (1 year) | -94.7% |
| Average daily value traded | 0.65M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Diamyd Medical AB is a Swedish biopharmaceutical company based in Stockholm that works on treatments for diabetes. Its main focus is a therapeutic vaccine candidate based on glutamic acid decarboxylase, aimed at preserving insulin-producing cells in people with type one diabetes. The company also develops related drug delivery technology and runs clinical studies with patients and healthcare partners in Sweden and elsewhere.
On this site Diamyd Medical AB (publ) appears as a stock on the Stockholm Exchange (Sweden), code DMYD-B, with prices in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Diamyd Medical AB (publ) (DMYD-B) trades on the Stockholm Exchange in Sweden. It last closed at SEK 1.010 on 20 October 2026.
Its price-based Market X-Ray is 18 out of 100 (a weak price profile), ranking 823 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 90.8% and over the last three months it fell 1.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 1 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -80.1% | ||
| From 52-week high | -94.3% | ||
| Momentum | 29 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -1.9% | ||
| 6-month return | -19.7% | ||
| 12-month return, skipping the last month | -90.7% | ||
| Stability (higher is calmer) | 2 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 231.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -94.7% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.65M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −3.6% |
|---|---|
| 1 month | −1.6% |
| 3 months | −1.9% |
| 6 months | −19.7% |
| 1 year | −90.8% |
| 3 years | −87.1% |
| 5 years | −95.8% |
Signals
| 50-day / 200-day average | 1.023 / 5.072 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.063 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.